Moshe Ornstein, MD
Immunotherapy combination regimens are likely to be the future of metastatic renal cell carcinoma (RCC) treatment, while agents such as interleukin-2 (IL-2) and nivolumab (Opdivo) monotherapy will continue to play an important role for these patients, according to Moshe Ornstein, MD, an oncology fellow at Cleveland Clinic.
State of the Science Summit on Genitourinary Cancers, Ornstein lectured on the obstacles physicians are facing with the use of immunotherapy for their patients with RCC. In an interview, he explained these challenges, the role of IL-2, and the future combinations that could change the RCC landscape.
OncLive: What did you discuss in your lecture on immunotherapy on kidney cancer?
We focused on the past, present, and the future. For the past, we talked about IL-2 and the role past immunotherapy has in 2017. For the current landscape of immunotherapy, we are really focusing on nivolumab, for which the approval was based on the phase III CheckMate-025 trial. What we tried to highlight were some of the challenges that clinicians and patients face when using nivolumab or any immunotherapy that may come down the road.
Lastly, after covering the past with IL-2 and the present with nivolumab, we focused on some of the future directions, which are combination strategies [involving] immunotherapy for metastatic RCC.
What role are you envisioning for IL-2 going forward as more modern immunotherapies take a front seat?
The benefit of IL-2, even now in 2017—when we have plenty of targeted therapies, such as nivolumab and probably other immunotherapeutics down the road in metastatic RCC—is that, for a subset of patients, this is one of the only therapies for which we have long-term data and long-term durable complete remissions (CRs).
... to read the full story